Key result
Statins cut ASCVD risk by inhibiting cholesterol synthesis and upregulating hepatic LDL receptors.
Answers are grounded in this paper and cite their sources.
This paper outlines the mechanism by which statins lower LDL-C to reduce atherosclerotic cardiovascular disease events and addresses an empiric approach to statin intolerance and noncompliance.
Statins are among the most widely prescribed drugs. They reduce risk for atherosclerotic cardiovascular disease by lowering serum apolipoprotein B-containing lipoproteins, particularly low-density lipoprotein (LDL) cholesterol (LDL-C).1 Statins inhibit cholesterol synthesis in the liver, which increases expression of LDL receptors and lowers serum LDL-C.2 The latter slows progression of atherosclerotic lesions, reduces coronary plaque rupture, and decreases likelihood of acute cardiovascular syndromes (ie, myocardial infarction and stroke).
No takes yet. Share an insight, caveat, or question.
Grundy et al. (2021) conducted a review in Atherosclerotic cardiovascular disease / Statin intolerance and noncompliance. Statins was evaluated. Statins lower serum LDL-C by inhibiting liver cholesterol synthesis and increasing LDL receptor expression, thereby reducing atherosclerotic cardiovascular disease risk.
Synapse has enriched 10 related papers. Consider them for comparative context: